Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Kilitch Drugs (India)
Small Cap•168 Employees•IPO 1994
Current Price
₹311.70
1.1 (0.35%)Updated
Today's Range
307
₹311.70
315.75
52 Week Range
52W Low₹299.95
52W High₹500.00
₹311.70
Downside3.92%
Upside60.41%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹567.86 Cr
Market Cap
Total market value of companyP/E Ratio
21.32
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
2.22
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹15.87
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
8.11%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
15.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
12.76%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
97.15%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
30.05%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
29.00%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
126.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.24
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹123.11
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
63.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •The company demonstrates robust quarterly profit growth, with a significant 126.00% increase in net profit for the latest reported quarter, indicating strong operational performance and efficiency gains.
- •Kilitch maintains a healthy quarterly sales growth of 29.00%, reflecting increasing demand for its products and effective market penetration within the competitive pharmaceuticals sector.
Weaknesses
6 points- •Quarterly net profit exhibits significant volatility, dropping from 10.22 Cr in March 2025 to 2.27 Cr in June 2025, raising concerns about earnings consistency and predictability for investors.
- •The absence of a dividend yield (0.00%) may deter income-focused investors seeking regular returns, potentially limiting the company's appeal to a broader investor base.
Opportunities
4 points- •The broader Pharmaceuticals sector is experiencing robust growth driven by increasing healthcare demand and innovation, presenting a favorable external environment for Kilitch to expand its market share.
- •Given its relatively smaller market capitalization of 686 Cr compared to industry giants, Kilitch has substantial room for growth through strategic market expansion and product portfolio diversification.
Threats
4 points- •Intense competition from larger, well-established pharmaceutical players with greater resources and market presence poses a significant threat to Kilitch's market share and pricing power.
- •Adverse changes in pharmaceutical regulations, drug pricing policies, or intellectual property laws could negatively impact the company's operational costs and profitability margins.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹333.47 | +₹21.77 | +6.98% |
| R3 | ₹324.72 | +₹13.02 | +4.18% |
| R2 | ₹320.23 | +₹8.53 | +2.74% |
| R1 | ₹315.97 | +₹4.27 | +1.37% |
| PIVOT | ₹311.48 | -0.22 | -0.07% |
| CURRENT | ₹311.70 | - | - |
| S1 | ₹289.72 | -₹21.98 | -7.05% |
| S2 | ₹298.47 | -₹13.23 | -4.25% |
| S3 | ₹302.73 | -₹8.97 | -2.88% |
| S4 | ₹307.22 | -₹4.48 | -1.44% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-2.7% vs avg
0.12L
(16 Mar 2026)Delivery %+9.4% vs avg
70.6%
(16 Mar 2026)Avg Volume (20D)20-day average
0.12L
(16 Feb - 16 Mar)Avg Delivery %Trend ↑
61.2%
(16 Feb - 16 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %
Peer Comparison
| Company Name |
|---|
 |
 Albert David Ltd |
 |
 Anuh Pharma Ltd |
 Haleos Labs Limited |
 Kopran Ltd |
 Medicamen Biotech Ltd |
 Medico Remedies Ltd |
 Sun Pharmaceutical Industries Ltd |
 Themis Medicare Ltd |
 Wanbury Ltd |
About
Kilitch Drugs (India) Ltd
Kilitch Drugs (India) Limited is a pharmaceutical company based in Mumbai, India, established in 1978. Their core business revolves around the development, manufacturing, and distribution of a wide array of pharmaceutical products within the Indian market and through exports.
A significant portion of their product portfolio consists of parenteral and nasal formulations. This includes medications targeting various therapeutic areas such as gastroenterology, pain management (NSAIDs, anticonvulsants), infectious diseases (antibacterial, antifungal, anti-malarial), cardiovascular health, and more. Specific examples mentioned include iron supplements for anemia treatment, metered nasal drops, and antibiotics like Klavmox and Onecef. They also offer a comprehensive range of vaccines and veterinary products.
Beyond parenterals and nasals, Kilitch Drugs produces a substantial line of oral medications. This includes diverse formulations like tablets, capsules, syrups, and powders catering to various therapeutic needs, including cardiovascular and diabetic conditions. Specific branded products like ROIPAR, DUREGRA, and ROIVIT (effervescent tablets and powders) and CELTINE (nutritional product) highlight the breadth of their offerings.
The company further expands its reach into topical treatments with C-Seal, a skin adhesive used in wound care. Their product line also extends into the cosmetics and herbal sectors. This includes a variety of skincare and haircare products (oils, creams, lotions, etc.), alongside herbal remedies aimed at addressing conditions like sore throats, prostate issues, and supplementing treatments for diabetes, obesity, and libido enhancement.
In summary, Kilitch Drugs (India) Limited operates a diversified pharmaceutical business with a broad product portfolio encompassing parenteral, nasal, and oral medications; topical treatments; cosmetics; and herbal remedies. Their operations include both domestic distribution within India and international exports, reflecting a substantial presence in the Indian pharmaceutical market.
COMPANY FACTS - KILITCH
Registered Address
37, Ujagar Industrial Estate, Waman Tukaram Patil Marg, Deonar
Mumbai
MAHARASHTRA
IN
Tel: 912261214100
Website:https://www.kilitch.com/
Investor Relations:http://www.kilitch.com/investor-relations/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 168
IPO Date: 14/02/1994
MANAGEMENT - KILITCH
Mr. Sunil Jain
Chief Financial Officer
Ms. Pushpa Nyoupane
Chief Compliance Officer, Company Secretary
Mr. Mukund Mehta
Managing Director, Executive Director
Mrs. Mira Mehta
Managing Director
Mr. Bhavin Mehta
Wholetime Director
Mr. Dipen Jain
Additional Non-Executive Independent Director
Prof. Murti Krishna
Non-Executive Independent Director
Mr. Venkita Rajan
Non-Executive Independent Director
Investor Questions Answered
Kilitch Drugs (India) Ltd (KILITCH) Stock FAQs
Get answers to the most common questions about Kilitch Drugs (India) Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Kilitch Drugs (India) Ltd (KILITCH) is ₹311.7. Today, the stock has gained by ₹1.10 (0.35%), trading in a range of ₹307 to ₹315.75. The stock opened at ₹314.35 with a trading volume of 11,692 shares.
Kilitch Drugs (India) Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹567.86 crores, P/E ratio of 21.32, ROE of 8.11%, and ROCE of 15.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Kilitch Drugs (India) Ltd (KILITCH) is ₹500, while the 52-week low is ₹299.95. Currently trading at ₹311.7, the stock is 5.9% away from its 52-week low and 37.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Kilitch Drugs (India) Ltd stock at ₹311.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 21.32 and P/B ratio of N/A. Today's performance shows a gain of 0.35%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Kilitch Drugs (India) Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹311.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Kilitch Drugs (India) Ltd's key financial metrics include: P/E Ratio: 21.32, P/B Ratio: N/A, ROE: 8.11%, ROCE: 15.70%, Dividend Yield: 0.00%, EPS: ₹15.87, Book Value: ₹123.11, Debt-to-Equity: 0.24, and Current Ratio: N/A. The company's market cap stands at ₹567.86 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Kilitch Drugs (India) Ltd stock opened at ₹314.35 and is currently trading at ₹311.7, showing a gain of ₹1.10 (0.35%). The intraday high is ₹315.75 and low is ₹307. The trading volume stands at 11,692 shares, indicating moderate market participation today.
Kilitch Drugs (India) Ltd has a Price-to-Earnings (P/E) ratio of 21.32, which means investors are willing to pay ₹21.32 for every ₹1 of earnings. With an EPS of ₹15.87, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Kilitch Drugs (India) Ltd has a market capitalization of ₹567.86 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹311.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Kilitch Drugs (India) Ltd has a book value of ₹123.11 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹311.7, which is 153.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Kilitch Drugs (India) Ltd has a Return on Equity (ROE) of 8.11% and Return on Capital Employed (ROCE) of 15.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Kilitch Drugs (India) Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Kilitch Drugs (India) Ltd has a debt-to-equity ratio of 0.24, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Kilitch Drugs (India) Ltd has an Earnings Per Share (EPS) of ₹15.87, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹311.7 and P/E ratio of 21.32, investors are paying 21.32 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Kilitch Drugs (India) Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Kilitch Drugs (India) Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Kilitch Drugs (India) Ltd stock, consider: 1) Fundamental Analysis - Review P/E (21.32), ROE (8.11%), debt-to-equity (0.24), and growth rates. 2) Technical Analysis - Check 52-week range (₹299.95 - ₹500.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹311.70) with book value (₹123.11) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Kilitch Drugs (India) Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹311.7 is 3017x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Kilitch Drugs (India) Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹299.95 - ₹500.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.24 indicates leverage. 4) Liquidity Risk - Based on trading volume of 11,692 shares. 5) Valuation Risk - P/E of 21.32 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Kilitch Drugs (India) Ltd operates in the industry with key metrics: P/E ratio of 21.32, ROE of 8.11%, market cap of ₹567.86 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.24), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Kilitch Drugs (India) Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹311.7, with a 52-week range of ₹299.95 to ₹500.00. Based on fundamentals like P/E (21.32), ROE (8.11%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Kilitch Drugs (India) Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹311.70. 2) Fundamental Deterioration - Declining ROE (currently 8.11%), increasing debt (D/E: 0.24), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Kilitch Drugs (India) Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu